Milnacipran: Beyond a role of antidepressant

Clinical Neuropharmacology

Volumn 32, Issue 6, 2009, Pages 355-363

  Pae, Chi Un ^a,b   Marks, David M ^a   Shah, Manan ^a   Han, Changsu ^a,c   Ham, Byung Joo ^d   Patkar, Ashwin A ^b   Masand, Prakash S ^b  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b DUKE UNIVERSITY   (United States)

^c Korea University   (South Korea)

^d Hallym University Medical Center   (South Korea)

Author keywords

Antidepressant; Anxiety; Fatigue; Fibromyalgia; Milnacipran; Pain

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MILNACIPRAN; NORADRENALIN; PAROXETINE; PLACEBO; SEROTONIN; SERTRALINE;

ANXIETY; ANXIETY DISORDER; CARDIOVASCULAR DISEASE; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIZZINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DYSURIA; FIBROMYALGIA; HEADACHE; HEART PALPITATION; HEART RATE; HOT FLUSH; HUMAN; HYPERTENSION; MAJOR DEPRESSION; MIGRAINE; NAUSEA; NEUROTRANSMISSION; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SWEATING; TREATMENT DURATION; VOMITING; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANXIETY; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FATIGUE; FIBROMYALGIA; HALF-LIFE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 73349096343     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181ac155b     Document Type: Review

References (75)

1. Moret C, Briley M. Effects of milnacipran and pindolol on extracellular noradrenaline and serotonin levels in guinea pig hypothalamus. J Neurochem 1997;69:815-822.
2. Moret C, Charveron M, Finberg JP, et al. Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl- cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 1985;24:1211-1219.
3. Obata H, Saito S, Koizuka S, et al. The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain. Anesth Analg 2005;100:1406-1410, table of contents.
4. Onal A, Parlar A, Ulker S. Milnacipran attenuates hyperalgesia and potentiates antihyperalgesic effect of tramadol in rats with mononeuropathic pain. Pharmacol Biochem Behav 2007;88: 171-178.
5. King T, Rao S, Vanderah T, et al. Differential blockade of nerve injury-induced shift in weight bearing and thermal and tactile hypersensitivity by milnacipran. J Pain 2006;7:513-520.
6. Puozzo C, Filaquier C, Briley M. Plasma levels of F1196, a novel antidepressant, after a single oral administration in volunteers. Brit J Clin Pharmacol 1985;20:1-29.
7. Puozzo C, Pozet N, Deprez D, et al. Pharmacokinetics of milnacipran in renal impairment. Eur J Drug Metab Pharmacokinet 1998;23: 280-286.
8. Boyer P, Briley M. Milnacipran, a new specific serotonin and noradrenaline reuptake inhibitor. Drugs Today (Barc) 1998; 34:709-720.
9. Leonard BE. The comparative pharmacology of new antidepressants. J Clin Psychiatry 1993;54(suppl):3-15; discussion 16-17.
10. Puozzo C, Lens S, Reh C, et al. Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants. Clin Pharmacokinet 2005;44:977-988.
11. Puozzo C, Hermann P, Chassard D. Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran. Int Clin Psychopharmacol 2006;21:153-158.
12. Puozzo C, Albin H, Vincon G, et al. Pharmacokinetics of milnacipran in liver impairment. Eur J Drug Metab Pharmacokinet 1998;23: 273-279.
13. Hindmarch I, Rigney U, Stanley N, et al. Pharmacodynamics of milnacipran in young and elderly volunteers. Br J Clin Pharmacol 2000;49:118-125.
14. Briley M, Prost JF, Moret C. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol 1996;11(suppl 4):9-14.
15. Palmier C, Puozzo C, Lenehan T, et al. Monoamine uptake inhibition by plasma from healthy volunteers after single oral doses of the antidepressant milnacipran. Eur J Clin Pharmacol 1989;37: 235-238.
16. Ansseau M, von Frenckell R, Mertens C, et al. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Psychopharmacology (Berl) 1989;98:163-168. (Pubitemid 19137726)
17. Macher JP, Sichel JP, Serre C, et al. Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology 1989;22:77-82.
18. Lecrubier Y, Pletan Y, Solles A, et al. Clinical efficacy of milnacipran: placebo-controlled trials. Int Clin Psychopharmacol 1996;11(suppl 4): 29-33.
19. Van Amerongen AP, Ferrey G, Tournoux A. A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression. J Affect Disord 2002;72:21-31.
20. Tignol J, Pujol-Domenech J, Chartres JP, et al. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Acta Psychiatr Scand 1998; 97:157-165.
21. Lopez-Ibor JJ, Conesa A. A comparative study of milnacipran and imipramine in the treatment of major depressive disorder. Curr Med Res Opin 2004;20:855-860.
22. Leinonen E, Lepola U, Koponen H, et al. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Acta Psychiatr Scand 1997;96:497-504.
23. Steen A, Den Boer JA. A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder. Int Clin Psychopharmacol 1997;12:269-281.
24. Ansseau M, Papart P, Troisfontaines B, et al. Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology (Berl) 1994;114:131-137. (Pubitemid 24150530)
25. Guelfi JD, Ansseau M, Corruble E, et al. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int Clin Psychopharmacol 1998;13:121-128.
26. Lee MS, Ham BJ, Kee BS, et al. Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression. Curr Med Res Opin 2005;21:1369-1375.
27. Ansseau M, von Frenckell R, Gerard MA, et al. Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine. Eur Neuropsychopharmacol 1991;1:113-121.
28. Clerc G. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Int Clin Psychopharmacol 2001;16:145-151.
29. Sechter D, Vandel P,Weiller E, et al. A comparative study of milnacipran and paroxetine in outpatients with major depression. J Affect Disord 2004;83:233-236.
30. Yang JCK, SW, Yu BH. Milnacipran versus sertraline in major depressive disorder: a double-blind randomized comparative study on the treatment effect and cbeta-adrenergic receptor responsiveness. Korean J Psychopharmacol 2003;14:387-396.
31. Puech A, Montgomery SA, Prost JF, et al. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 1997;12: 99-108.
32. Kasper S, Pletan Y, Solles A, et al. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharmacol 1996;11(suppl 4):35-39.
33. Lopez-Ibor J, Guelfi JD, Pletan Y, et al. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 1996;11(suppl 4):41-46.
34. Nakagawa A, Watanabe N, Omori IM, et al. Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants: a systematic review and meta-analysis. CNS Drugs 2008;22:587-602.
35. Rouillon F, Warner B, Pezous N, et al. Milnacipran efficacy in the prevention of recurrent depression: a 12-month placebo-controlled study. Milnacipran recurrence prevention study group. Int Clin Psychopharmacol 2000;15:133-140.
36. Rouillon F, Berdeaux G, Bisserbe JC, et al. Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life. J Affect Disord 2000;58:171-180.
37. Kanemoto K, Matsubara M, Yamashita K, et al. Controlled comparison of two different doses of milnacipran in major depressive outpatients. Int Clin Psychopharmacol 2004;19:343-346.
38. von Frenckell R, Ansseau M, Serre C, et al. Pooling two controlled comparisons of milnacipran (F2207) and amitriptyline in endogenous inpatients. A new approach in dose ranging studies. Int Clin Psychopharmacol 1990;5:49-56.
39. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum 1990;33:160-172.
40. White KP, Harth M. Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep 2001;5:320-329.
41. Arnold LM, Hudson JI, Keck PE, et al. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry 2006;67:1219-1225.
42. Arnold LM. Management of fibromyalgia and comorbid psychiatric disorders. J Clin Psychiatry 2008;69(suppl 2):14-19.
43. Pae CU, Luyten P, Marks DM, et al. The relationship between fibromyalgia and major depressive disorder: a comprehensive review. Curr Med Res Opin 2008;24:2359-2371.
44. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32:1975-1985.
45. Vitton O, Gendreau M, Gendreau J, et al. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004;19(suppl 1):S27-S35.
46. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-2984.
47. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119:5-15.
48. Arnold LM, Pritchett YL, D'Souza DN, et al. Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials. J Womens Health (Larchmt) 2007;16:1145-1156.
49. Iyengar S, Webster AA, Hemrick-Luecke SK, et al. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004;311:576-584.
50. Hunt SP, Mantyh PW. The molecular dynamics of pain control. Nat Rev Neurosci 2001;2:83-91.
51. McHugh JM, McHugh WB. Pain: neuroanatomy, chemical mediators, and clinical implications. AACN Clin Issues 2000;11:168-178.
52. Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988-2004.
53. Clauw DP, Palmer RH, Vitton O, et al. The Efficacy and Safety of Milnacipran in the Treatment of fibromyalgia. Presented at the 24th Annual American Academy of Pain Medicine Meeting on February 12-16, Orlando, Fla. 2008.
54. Goldenberg DC, DJ, Palmer RH, et al. One-Year Durability of Response to Milnacipran Treatment for Fibromyalgia. Presented at the 24th Annual American Academy of Pain Medicine Meeting February 12-16, Orlando, Fla. 2008.
55. Perahia DG, Pritchett YL, Desaiah D, et al. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol 2006;21:311-317.
56. Aggarwal VR, McBeth J, Zakrzewska JM, et al. The epidemiology of chronic syndromes that are frequently unexplained: do they have common associated factors? Int J Epidemiol 2006;35:468-476.
57. Perrot S. Fibromyalgia syndrome: a relevant recent construction of an ancient condition? Curr Opin Support Palliat Care 2008;2:122-127.
58. Gur A, Oktayoglu P. Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: new concepts in treatment. Curr Pharm Des 2008;14:1274-1294.
59. Matsuzawa-Yanagida K, Narita M, Nakajima M, et al. Usefulness of antidepressants for improving the neuropathic pain-like state and pain-induced anxiety through actions at different brain sites. Neuropsychopharmacology 2008;33:1952-1965.
60. Moojen VK, Martins MR, Reinke A, et al. Effects of milnacipran in animal models of anxiety and memory. Neurochem Res 2006;31: 571-577.
61. Bourin M, Masse F, Dailly E, et al. Anxiolytic-like effect of milnacipran in the four-plate test in mice: mechanism of action. Pharmacol Biochem Behav 2005;81:645-656.
62. Blaya C, Seganfredo AC, Dornelles M, et al. The efficacy of milnacipran in panic disorder: an open trial. Int Clin Psychopharmacol 2007;22:153-158.
63. Gama CS, Zanatto VC, Picon F, et al. Efficacy of milnacipran in treating anxiety symptoms in schizophrenic patients receiving clozapine: a case series study. Rev Bras Psiquiatr 2006;28:339-340.
64. Pollack M, Mangano R, Entsuah R, et al. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl) 2007;194:233-242. (Pubitemid 47457944)
65. Pollack MH, Lepola U, Koponen H, et al. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 2007;24:1-14.
66. Allgulander C, Hartford J, Russell J, et al. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials. Curr Med Res Opin 2007;23: 1245-1252.
67. Koponen H, Allgulander C, Erickson J, et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry 2007;9: 100-107.
68. Delini-Stula A. Milnacipran: an antidepressant with dual selectivity of action on noradrenaline and serotonin uptake. Hum Psychopharmacol 2000;15:255-260.
69. Sachs-Ericsson N, Joiner T, Blazer DG. The influence of lifetime depression on self-reported memory and cognitive problems: results from the National Comorbidity SurveyVReplication. Aging Ment Health 2008;12:183-192.
70. Glass JM. Cognitive dysfunction in fibromyalgia and chronic fatigue syndrome: new trends and future directions. Curr Rheumatol Rep 2006;8:425-429.
71. Poirier MF, Galinowski A, Amado I, et al. Double-blind comparative study of the action of repeated administration of milnacipran versus placebo on cognitive functions in healthy volunteers. Hum Psychopharmacol 2004;19:1-7.
72. Kimura M, Kanetani K, Imai R, et al. Therapeutic effects of milnacipran, a serotonin and noradrenaline reuptake inhibitor, on post-stroke depression. Int Clin Psychopharmacol 2002;17: 121-125.
73. Yamakawa Y, Satoh S, Sawa S, et al. Efficacy of milnacipran on poststroke depression on inpatient rehabilitation. Psychiatry Clin Neurosci 2005;59:705-710.
74. Kanetani K, Kimura M, Endo S. Therapeutic effects of milnacipran (serotonin noradrenalin reuptake inhibitor) on depression following mild and moderate traumatic brain injury. J Nippon Med Sch 2003; 70:313-320.
75. Benarroch EE. Descending monoaminergic pain modulation: bidirectional control and clinical relevance. Neurology 2008;71: 217-221.